---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-006727"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:13:42.187571+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics receives Nasdaq deficiency notice for bid price below $1; 180-day cure period

## Summary
- Received Nasdaq notice on Jan 21, 2025, for failing minimum bid price of $1.00 for 30 consecutive business days through Jan 17, 2025.
- Has until July 21, 2025 (180-day Compliance Period) to regain compliance by closing bid at $1 for at least 10 consecutive days.
- May implement reverse stock split to meet bid price requirement; must complete split no later than 10 business days before deadline.
- Also considering transfer of listing to Nasdaq Capital Market if unable to regain compliance on Global Market.
- Listing not immediately affected; company intends to monitor and take measures to regain compliance.

## SEC filing metadata
- accession: 0001213900-25-006727
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/0001213900-25-006727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/ea0228747-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-006727
- JSON: https://secwatch.observer/filing/0001213900-25-006727.json
- Plain text: https://secwatch.observer/filing/0001213900-25-006727.txt

## Source-grounded claims
- claim_id: 810922463bb1e58ab7e0270347f6baafd7b8c218
  claim: RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
  evidence_excerpt: January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/0001213900-25-006727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.